Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22777751 | 0.79 | BACE1 (0.50) | KMT2ACNR2TBXA2RBACE1NUDT1 | |
| SCHEMBL23100707 | 0.77 | KMT2A (0.47) | KMT2ATBXA2RBACE1NUDT1TDP1 | |
| SCHEMBL22495127 | 0.76 | — | — | |
| SCHEMBL4159853 | 0.75 | KMT2A (0.49) | KMT2ATBXA2RBACE1NUDT1TSHR | |
| SCHEMBL16236226 | 0.75 | KMT2A (0.45) | KMT2ATBXA2RBACE1NUDT1TDP1 | |
| SCHEMBL22788728 | 0.73 | KMT2A (0.46) | KMT2ATBXA2RBACE1NUDT1TDP1 | |
| SCHEMBL17194629 | 0.73 | BACE1 (0.47) | KMT2ATBXA2RBACE1NUDT1TDP1 | |
| SCHEMBL15415545 | 0.73 | KMT2A (0.46) | KMT2ATBXA2RBACE1NUDT1TDP1 | |
| SCHEMBL22788758 | 0.73 | BACE1 (0.47) | KMT2ACNR2TBXA2RBACE1NUDT1 | |
| SCHEMBL23100636 | 0.73 | BACE1 (0.63) | KMT2ATBXA2RBACE1NUDT1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728220-B1 | PHARMACEUTICAL COMPOUNDS | REVIRAL LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| US-11141406-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-10-12 | — | — | US | disclosed |
| US-11141406-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-10-12 | — | — | US | disclosed |
| US-11078189-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-08-03 | — | — | US | disclosed |
| US-11078189-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-08-03 | — | — | US | disclosed |
| EP-3728220-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-20200316030-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-10-08 | — | — | US | disclosed |
| US-20200316030-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-10-08 | — | — | US | disclosed |
| CN-111465600-A | Pharmaceutical compounds | 瑞威有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-06-04 | — | — | US | disclosed |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-06-04 | — | — | US | disclosed |
| WO-2019016566-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141406-B2 | Pharmaceutical compounds | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | KMT2A 3234/4885CNR2 31/4885TBXA2R 1810/4885 |
| US-20200316030-A1 | PHARMACEUTICAL COMPOUNDS | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | KMT2A 3134/4885CNR2 34/4885TBXA2R 1686/4885 |
| US-11078189-B2 | Pharmaceutical compounds | HRH4, CHRM5, CHRM1 | KMT2A 1448/4885CNR2 24/4885TBXA2R 2134/4885 |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | HRH4, CHRM5, CHRM1 | KMT2A 1448/4885CNR2 24/4885TBXA2R 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.